Market Place
Sourcing Support
Bristol Myers Squibb completes acquisition of Forbius
22 Sep 2020 //
PHARMABIZ
Bristol Myers Squibb Completes Acquisition of Forbius
21 Sep 2020 //
BUSINESSWIRE
BMS agrees to acquire biotherapeutics developer Forbius
25 Aug 2020 //
PHARMACEUTICALTECHNOLOGY
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta
24 Aug 2020 //
BIOSPACE
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta
24 Aug 2020 //
BUSINESSWIRE
Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200
08 Nov 2019 //
BUSINESSWIRE
Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200
14 Oct 2019 //
BUSINESSWIRE
Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100
11 Oct 2019 //
BUSINESS WIRE
Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200
24 Apr 2019 //
BUSINESSWIRE
Forbius Announces First Patient Dosed in Ph2a EGFR-Overexpressing (TNBC)
23 Apr 2019 //
BUSINESSWIRE
Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR
01 Apr 2019 //
BUSINESSWIRE
Forbius Announces First Patient Dosed in Ph 2a (SCCHN) Trial of AVID100
07 Mar 2019 //
BUSINESSWIRE
Forbius Announces the First Patient Dosed in a Phase 1b Trial of AVID200
05 Mar 2019 //
BUSINESSWIRE
Forbius Awarded $18.8 Million Grant by CPRI of Texas
24 Aug 2018 //
BUSINESSWIRE
Forbius (Formation Biologics) Awarded $18.8 Million Grant
24 Aug 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.